Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol

Figure 2

Dose escalation scheme of ParvOryx01 for the 1 st study group. The numbers (1, 2, or 3) depict the dose level for the next patient. Red arrows denote a dose limiting event in this patient and black arrows a patient tested without an event. Trial stops at the bottom line or whenever a dose level of zero is reached.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us